PF-4 Inhibitors
PF-4 inhibitors belong to a specific chemical class of compounds that target Platelet Factor 4 (PF-4), also known as CXCL4, which is a small cytokine produced by activated platelets. PF-4 plays a role in various physiological and pathological processes, including inflammation, immune response, and thrombosis. Inhibiting PF-4 have implications in various diseases and conditions. PF-4 inhibitors are designed to interact with PF-4 and modulate its biological activity, affecting its binding to receptors, signaling pathways, or interaction with other molecules.
The study of PF-4 inhibitors is an active area of research in the field of molecular and cell biology. Scientists aim to gain a deeper understanding of the structural and functional aspects of PF-4 and its roles in cellular processes. By specifically targeting PF-4, these inhibitors provide valuable tools for investigating the biological functions of this cytokine and its involvement in various physiological and pathological processes. Researchers are actively investigating the precise mechanisms by which PF-4 inhibitors interact with the cytokine and how they impact its activity and function. By elucidating the molecular pathways involved, scientists hope to uncover valuable insights into the complex regulatory mechanisms that govern PF-4-mediated cellular responses.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Aspirin | 50-78-2 | sc-202471 sc-202471A | 5 g 50 g | $20.00 $42.00 | 4 | |
Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production, a potent activator of platelets. This leads to decreased platelet aggregation and, consequently, reduced release of PF-4 from platelets. | ||||||
Ibuprofen | 15687-27-1 | sc-200534 sc-200534A | 1 g 5 g | $53.00 $88.00 | 6 | |
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits COX enzymes, decreasing prostaglandin synthesis. Reduced prostaglandin levels limit platelet aggregation and thus PF-4 release. | ||||||
Clopidogrel | 113665-84-2 | sc-507403 | 1 g | $122.00 | 1 | |
Clopidogrel selectively inhibits the P2Y12 receptor on platelets, reducing ADP-mediated platelet aggregation. This action indirectly decreases PF-4 secretion by inhibiting platelet activation. | ||||||
Ticagrelor | 274693-27-5 | sc-472972 sc-472972A sc-472972B sc-472972C | 10 mg 25 mg 50 mg 100 mg | $104.00 $228.00 $270.00 $302.00 | ||
Ticagrelor is a reversible inhibitor of the P2Y12 receptor, preventing ADP-induced platelet aggregation. By hindering platelet activation, it indirectly reduces PF-4 release. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole inhibits phosphodiesterase, leading to an increase in cAMP within platelets, which inhibits platelet activation. This indirectly suppresses PF-4 release by preventing platelet aggregation. | ||||||
Apixaban | 503612-47-3 | sc-364406 sc-364406A | 10 mg 50 mg | $240.00 $634.00 | 2 | |
Apixaban directly inhibits Factor Xa, reducing thrombin formation and subsequent platelet activation. Lower levels of platelet activation result in decreased PF-4 release. | ||||||
Rivaroxaban | 366789-02-8 | sc-208311 | 2 mg | $158.00 | 18 | |
Rivaroxaban is a direct Factor Xa inhibitor, reducing thrombin generation and platelet activation. This mechanism indirectly leads to reduced PF-4 secretion. | ||||||
Warfarin | 81-81-2 | sc-205888 sc-205888A | 1 g 10 g | $73.00 $246.00 | 7 | |
Warfarin inhibits the vitamin K epoxide reductase complex, decreasing the synthesis of vitamin K-dependent coagulation factors. This reduction in coagulation factor activity indirectly diminishes PF-4 release by lowering platelet activation. | ||||||
Tirofiban-d6 | 144494-65-5 (unlabeled) | sc-475655 | 1 mg | $450.00 | ||
Tirofiban-d6 blocks the GPIIb/IIIa receptor, hindering platelet aggregation. This action indirectly reduces the availability and activity of PF-4 by limiting platelet activation. | ||||||
Heparin | 9005-49-6 | sc-507344 | 25 mg | $119.00 | 1 | |
Heparin binds to antithrombin III, enhancing its activity to inhibit thrombin and Factor Xa. This anticoagulant effect indirectly reduces PF-4 release by decreasing thrombin-mediated platelet activation. | ||||||